Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.

Current opinion in oncology - 1 Nov 2007

Vanden Bempt Isabelle, Drijkoningen Maria, De Wolf-Peeters Christiane

Abstract excerpt

PURPOSE OF REVIEW: We discuss recent findings on the genotypic alterations associated with HER2-positive breast cancer in an attempt to clarify the clinical heterogeneity observed among these tumors. RECENT FINDINGS: Molecular genetic analysis supports the distinctive nature of HER2-positive breast cancer, which is primarily driven by HER2 gene amplification. Depending on the amplicon size, a variety of genes can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aneuploidy
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 17

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Genes, erbB-2

Share to Genetic Techniques

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 17906451
DOI: 10.1097/CCO.0b013e3282f0ad8e

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.PMID 17906451Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedSemantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

<i>HER2</i> genetic heterogeneity in breast carcinomaSemantic proximity Read ↗

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read ↗

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistrySemantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

DNA amplifications in breast cancer: genotypic-phenotypic correlations.Semantic proximity Read ↗

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.Semantic proximity Read ↗

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.